Edgewise Therapeutics, Inc.(EWTX)

POST45.40-0.01-0.02%19:35 EDT

45.41-2.94-6.08%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says
  MT Newswires Live · 07-09 23:17
  Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says
- Oppenheimer Initiates Edgewise Therapeutics at Outperform
  MT Newswires Live · 07-09 20:19
  Oppenheimer Initiates Edgewise Therapeutics at Outperform
- Edgewise Therapeutics initiated with an Outperform at Oppenheimer
  TIPRANKS · 07-09 19:10
  Edgewise Therapeutics initiated with an Outperform at Oppenheimer
- Edgewise Therapeutics is Maintained at Buy by Guggenheim
  Dow Jones · 07-06
  Edgewise Therapeutics is Maintained at Buy by Guggenheim
- Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
  TIPRANKS · 07-06
  Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
- Top Edgewise Therapeutics Executive Makes Major Move With Insider Stock Sale
  TIPRANKS · 07-03
  Top Edgewise Therapeutics Executive Makes Major Move With Insider Stock Sale
- Edgewise Therapeutics CSO Alan J. Russell Sells 200,000 Common Shares Worth $7.88 Million
  Reuters · 07-03
  Edgewise Therapeutics CSO Alan J. Russell Sells 200,000 Common Shares Worth $7.88 Million
- Edgewise Therapeutics Grants Inducement Stock Options for 16,500 Shares at $40.63 Each
  Reuters · 07-01
  Edgewise Therapeutics Grants Inducement Stock Options for 16,500 Shares at $40.63 Each
- Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules
  THOMSON REUTERS · 07-01
  Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules
- Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release
  Simply Wall St. · 06-26
  Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release
- Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says
  MT Newswires Live · 06-17
  Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says
- Edgewise Therapeutics Is Maintained at Neutral by Goldman Sachs
  Dow Jones · 06-17
  Edgewise Therapeutics Is Maintained at Neutral by Goldman Sachs
- RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk
  MT Newswires Live · 06-17
  RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk
- Edgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs
  TIPRANKS · 06-17
  Edgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs
- Edgewise Therapeutics price target raised to $52 from $50 at Leerink
  TIPRANKS · 06-17
  Edgewise Therapeutics price target raised to $52 from $50 at Leerink
- Edgewise Therapeutics Reports Improvements In Heart Drug Trial
  Benzinga · 06-17
  Edgewise Therapeutics Reports Improvements In Heart Drug Trial
- Edgewise Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co.
  Dow Jones · 06-17
  Edgewise Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co.
- Buy Rating Reiterated on Edgewise Therapeutics as Strong EDG-7500 Data and Asset Sale Support Cardiovascular Pipeline; $45 Price Target Unchanged
  TIPRANKS · 06-16
  Buy Rating Reiterated on Edgewise Therapeutics as Strong EDG-7500 Data and Asset Sale Support Cardiovascular Pipeline; $45 Price Target Unchanged
- Edgewise Therapeutics falls -9.9%
  TIPRANKS · 06-16
  Edgewise Therapeutics falls -9.9%
- BUZZ-Edgewise reports mid-stage trial data for heart disease drug, shares fall
  Reuters · 06-16
  BUZZ-Edgewise reports mid-stage trial data for heart disease drug, shares fall
Company Profile
Company Name
Edgewise Therapeutics, Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.edgewisetx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.
- 07-01
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 06-05
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-01
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 05-07
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 05-07
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-07
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 05-06
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 03-27
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 02-26
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 02-26
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 01-22
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 01-20
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 01-15
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2025-12-29
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities

1D
5D
Day
Week
Month

Loading ...

High

48.14

Open

48.09

Volume%

0.80

Low

43.81

48.35

T/O Rate

1.59%

To The Moon

Edgewise Therapeutics, Inc.(EWTX)

Company Profile

Most Discussed